The antibody and HLA-restricted virus-specific cytotoxic T lymphocyte (CTL) responses to influenza vaccine of 36 volunteers were analysed. Three vaccines were used: a live attenuated, and two types of inactivated, a whole virus and a purified surface antigen vaccine. Antibody to haemagglutinin (HA) was assayed using plaque neutralization, single-radial-haemolysis and haemagglutination-inhibition (HI) techniques. Antibodies to nucleoprotein and matrix antigens were also measured. Most of the volunteers had antibody responses to the HA in the inactivated vaccines which were detected by all three techniques. Nine of the twelve recipients of the live virus vaccine did not have an antibody response detected by the HI test, but four of these did have antibody responses when the plaque neutralization test was used. Single-radial-haemolysis was more sensitive than the HI test for detecting low levels of antibody, but the plaque neutralization test was the most sensitive for detecting low levels of antibody. Most volunteers had a rise in their HLA-restricted influenza-specific memory CTL response, but three recipients of live vaccine who did not have an antibody response by any technique also did not have an increase in their cytotoxic T cell activity. Three volunteers, two of whom had received live vaccine, had a positive CTL response without antibody response.
INTRODUCTION
It has become evident that many virus infections induce a cytotoxic T lymphocyte (CTL) response and the killer T cells which are generated express restriction for self (H-2 antigen in mice and HLA in man) as well as virus specificity (Doherty et al., 1976) . Influenza virus infection of mice has been shown to induce a CTL response (Effros et al., 1977; Zweerink et aL, 1977; Yap &Ada, 1977; Ennis et al., 1977 a) . Inactivated influenza vaccine has also been reported to be capable of inducing a CTL response in mice (Ennis et al., 1977b) , but in two studies the relative ability of a subunit vaccine to induce a CTL response was less than a whole virus vaccine (Webster & Askonas, 1980; Reiss & Schulman, 1980) . We recently noted in a small human study that infection with a live influenza virus induced an HLA-restricted CTL in four of five young adult volunteers (Daisy et al., 1981) . Earlier, we had reported that a large dose of whole virus vaccine which contained 60 /lg of A/USSR/92 haemagglutinin (HA) induced a lymphocyte response in some vaccine recipients which was cytotoxic on autologous cells infected with influenza virus, but we did not analyse whether these cytotoxic lymphocytes were HLA-restricted (Quinnan et al., 1980) . Recently, McMichael et al. (1981) reported the augmentation of memory HLArestricted CTL response in five out of eight recipients of whole virus vaccine and in three out 0022-1317/82/0000-4821 $02.00 © 1982 SGM of nine who had received a subunit vaccine. The present study was designed to analyse whether live attenuated, inactivated whole or surface antigen influenza vaccines induced an HLA-restricted CTL response which could be detected directly by using peripheral blood lymphocytes as effectors, and whether the vaccines augmented the influenza-specific memory CTL response detected after in vitro stimulation of lymphocytes with viruses. The detailed results of the cytotoxicity assays are being pubfished separately. This paper reports the comparative results of the humoral antibody response to the haemagglutinin antigen measured by haemagglutination-inhibition (HI), single-radialhaemolysis (SRH) and plaque neutralization (PN) techniques. The antibody responses determined by these techniques were correlated with the results of the HLA-restricted virusspecific CTL assays. Several reports (Schild et al., 1975; Russell et al., 1975; Oxford et al., 1981; Farrohi et al., 1977) have indicated that antibody results detected by SRH were comparable to those detected by HI testing. We wanted to analyse the relationship of the antibody response to the CTL response, so we also measured antibodies by a PN technique. Earlier, we reported that low levels of plaque neutralizing antibody to mumps virus, which were not detected in an HI test, were associated with protection against infection during an outbreak (Ennis, 1969) . In addition to comparing the HLA-restricted CTL responses to the antibody to the HA measured by these techniques, we assayed the antibody responses to nucleoprotein and matrix antigens.
METHODS

Vaccines.
A live attenuated virus vaccine was supplied by Smith Kline-RIT, B1330 Rixensart, Belgium and contained A/California/10/78 (H1N1) surface antigen similar to A/Brazil/l 1/78. It was produced by recombination with A/PR/8/34 and was inhibitorresistant. This vaccine had been given to 80 volunteers without adverse effect in an earlier study (Delem et al., 1981) . It was given intranasally as drops and each dose contained 106.o EID~o. The inactivated vaccines were supplied by Glaxo and represented a sucrose gradientpurified whole virus vaccine, and a detergent-disrupted and subsequent separation of surface antigens to make a surface antigen vaccine. The inactivated vaccines each contained 15 ag of A/Brazil/11/78 HA.
Antibody assays. The HI test was performed as previously described (Pereira et al., 1964) . The SRH gel plates containing purified virus adsorbed to sheep erythrocytes were prepared as described previously (Oxford et al., 1981) . Sera were heat-inactivated at 56 °C for 30 min and 5 gl of undiluted serum was added to 3 mm wells in the immunoplates. The plates were incubated at 37 °C for 16 h before they were read. The PN was performed on MDCK cell monolayers in Linbro plastic plates with 35 mm wells. A 0.1 ml sample of virus diluted in phosphate-buffered saline pH 7.2, with 1% bovine serum albumin, was incubated with 0.1 ml diluted serum for 30 min at 37°C. After incubation, 0.1 ml of the virus-serum mixture was added to the wells to yield about 30 plaques per well when the agar was removed 3 days later, and the cells were fixed and stained with 0.1% naphthalene black, 6 % glacial acetic acid and 1.36% sodium acetate. The overlay medium used contained trypsin as described (Appleyard & Maber, 1974 ). An average reduction of plaques by 50% was interpreted as being positive for antibody at that dilution and two wells were used at each serum dilution.
Cytotoxicity assays
Preparation of lymphocytes. Volunteers' lymphocytes had been HLA-typed by standard serological techniques prior to this study. Approximately 50 ml of peripheral blood containing 50 units of preservative-free heparin was diluted with 0-5 vol. of medium (RPMI, Gibco) and layered on to Ficoll-Paque gradients (Pharmacia). These preparations were centrifuged and the layered buffy coat removed and washed with medium three times. The cells were then counted and placed in medium with 10% foetal calf serum and an aliquot was used to infect target cells, and another aliquot was restimulated in vitro with virus for 7 days before being used as effector cells (McMichael et al., 1977) . Target cells. These were prepared by adding 1000 haemagglutinating units of viruscontaining allantoic fluid (0.5 ml of either A/Brazil/11/78 or B/Hong Kong/5/73) or medium to 5 x 106 lymphocytes prepared from the blood of each of five volunteers which were preselected to be used as target cells based on HLA typing results, in 0.5 ml of medium. A 0.1 ml amount of 51Cr (Amersham International) was then added. After incubation at 37 °C for 90 min, the target cells were washed twice with medium and were then reincubated at 37 °C in medium with 10% foetal calf serum for 5 more h before effect0r cells were added.
Effector cells. These were diluted in medium to obtain 50:1 or 25:1 effector :target ratios on to 0-1 ml of target cell suspension, containing 104 cells per well in round-bottomed microtitre plates. Each effector was tested in four replicate wells each on uninfected, A/Brazil/l 1/78-and B/Hong Kong/'5/73-infected target cells. The microtitre plates were placed at 37 °C in 5% CO 2 for 6 h before harvesting with Titertek harvesting frames and the specific immune lysis calculated (Ennis et al., 1977 c) .
RESULTS
Antibody responses to vaccines
The data presented in Table 1 summarize the antibody responses to A/Brazil/l 1/78 in 13 volunteers who received the inactivated whole virus vaccine. There were nine individuals who had low pre-vaccination levels of antibody detected by PN but not by HI or SRH. Twelve had a fourfold or greater rise in antibody titre in the HI and PN test, but one volunteer (no. 49) did not have an antibody rise by any technique. The post-vaccination antibody titres determined by HI and PN were similar.
Antibody responses of 11 volunteers to the surface antigen vaccine are summarized in did not have antibody responses had a fairly high level of antibody before vaccination detected in all three assays, and the other two non-responders had no or a low antibody level respectively, prior to vaccination. The mean antibody titres in this group were higher than in the other two groups prior to vaccination, and the post-vaccination antibody responses were lower than those of the inactivated vaccine groups. Fig. 1 demonstrates the correlation between antibody titres determined before and 21 days after vaccination measured by the SRH technique and compared to those detected by HI and PN assays. Overall, the correlation between antibody titre measured by HI and SRH was moderately high (r = 0.82) but there were 11 sera which had antibodies by SRH testing which were negative by HI test. No serum which was positive by HI was negative in the SRH test.
There was also very good correlation (r = 0.85)between antibody levels measured by SRH and PN, but the PN test detected low levels of antibody in several sera which were negative in the SRH test (Fig. 1) .
Antibody responses to the internal nucleoprotein (NP) antigen are contained' in Table~.4. Most of the volunteers in all three vaccine groups had a detectable level of antibody to NP prior to vaccination. Of those without pre-existing antibody to NP, one who received whole virus vaccine, two who were given the surface antigen vaccine and none who received the live vaccine developed antibody to NP after vaccination. There was a moderate boost 1~ A. ENNIS, Q. YI-HUA AND G. C. SCHILD in the mean antibody to NP in the recipients of the surface antigen vaccine, a lesser increase in the recipients of the whole virus vaccine and no rise in those who received the live virus vaccine. Antibody responses to matrix antigen were also assessed by single-radial-immunodiffusion, but we did not detect any matrix antibody before or after vaccination. Table 5 lists for comparison the antibody and HLA-restricted virus-specific CTL responses of a number of the volunteers. Most of the volunteers had both an antibody response and a CTL response and the results of no. 33 and no. 36 of the live vaccine group, no. 19 of the whole virus group, and no. 20 and no. 38 of the surface antigen group are given as several examples of the positive responses. The remaining individuals in Table 5 are all of the volunteers who had only an antibody or a CTL response, or neither. Volunteers no. 21, 24 and 39 presumably were not infected with the live virus because they did not develop antibody or CTL responses after vaccination. Five other recipients of live vaccine did not have an antibody response detected by HI tests, but three of these had a rise in PN antibody and all five had a positive CTL response. On the other hand, two recipients of whole virus vaccine (no. 22 and 25) had antibody responses but no CTL response was detected. All of the recipients of the surface antigen vaccine had both antibody and CTL responses, as did the other volunteers in the live and whole virus groups whose results are not included in Table 5 . DISCUSSION The results indicate that the majority of individuals given the live attenuated vaccine, and two types of inactivated vaccine, whole virus or surface antigen, developed humoral antibody and HLA-restricted virus-specific CTL responses. Antibodies to the haemagglutinin, which is the major surface antigen, were measured by the HI, SRH and PN techniques. Sera which had antibody detected at />1 "10 by HI were similarly positive and correlated well with titres measured by the SRH or the PN assay. The SRH technique detected antibody in 11/24 individuals who did not have antibody in the HI test; moreover, of 13 sera which were negative by SRH, 10 had antibody detected by the PN test. Two sera had low levels of antibody in the SRH test and were negative in the PN test.
These results confirm reports that antibody titres determined by SRH generally correlated with those measured in HI tests. This has been noted with influenza viruses (Schild et al., 1975; RusseU et al., 1975; Oxford et al., 1981; Farrohi et al., 1977) and other viruses including mumps (Norrby et al., 1977; V~i~n~inen et al., 1976) and rubella (Clarke et al., 1977; Gaidamovich et al., 1980) . Several of these authors commented on the ability to measure lower levels of antibody by SRH than in the HI test because the sera did not have to be treated to remove non-specific inhibitors of haemagglutination. In this study we also measured antibodies by PN and the results indicate that this test detected low levels of antibodies in sera which were not detected by either the HI or SRH test. However, it should be noted that although the PN was the most sensitive test at a low serum antibody concentration, it is a much more complex and time-consuming procedure than the HI and SRH assays.
We performed these three assays to better define the pre-existing antibody status and the antibody responses to the vaccines for comparison with the influenza virus-specific HLArestricted CTL responses in the volunteers. Although 9/12 volunteers in the live vaccine group did not have an HI antibody response, four of these were positive by the PN test. Three volunteers had neither an antibody nor a CTL response to the live virus, so presumably they were not infected. Two others, who had no antibody response in any assay, did develop a positive CTL response, as did three other live vaccine recipients who had antibody responses detected by PN but not HI tests. In the whole virus group, 10/13 had both antibody and CTL responses. Two did develop antibodies but no CTL response, and one had a CTL response in the absence of a rise in antibody. All 11 of the recipients of surface antigen vaccine had both antibody and CTL responses. The individuals in the surface antigen vaccine group all had pre-existing PN antibody, so the antibody and CTL responses were clearly occurring in individuals primed to HI haemagglutinin by natural infection.
There were some increases in antibody to NP detected in the recipients of the surface antigen and whole virus vaccines, but not in any of the recipients of the live attenuated vaccine. The number of individuals with a response to NP antigen was five in the surface antigen vaccine group, one in the whole virus group and none after the live virus vaccine. The relatively greater NP antibody response in the recipients of the surface antigen vaccine is interesting because the vaccine is made by detergent disruption of sucrose gradient-purified whole virus and is then enriched for surface antigen on sucrose gradients. Although nucleoprotein antibody is induced by influenza infections, we are not aware of other studies which have analysed the response to surface antigen vaccine using the technique of single-radialimmunodiffusion. An earlier report (Oxford et al., 1979) indicated that whole virus and ether-split virus vaccines boosted antibodies to NP in about 35 % of recipients. The numbers of individuals in the vaccine groups in the present study were not large and these observations should be analysed in future investigations.
Recently, it has been reported (Yewdell et al., 1981) that NP antigen could be detected on the surface of influenza-infected P815 cells by using several monoclonal antisera to NP antigen. Although the infected cells expressed more haemagglutinin and neuraminidase antigen on their surfaces than NP, they did not detect matrix antigen to the same degree as NP. The authors indicated that since NP antigen is on influenza-infected cells, it could also be recognized by the cross-reactive cytotoxic T lymphocytes which have been detected in mice (Effros et al., 1977; Zweerink et al., 1977; Yap & Ada, 1977; Ennis et aL, 1977c) and humans. The present data would not suggest that the NP antigen is responsible for the increase in CTL responses which occurred in most of the recipients of these three vaccines. Most of the volunteers had a good antibody response to HA and did not have an 
